# US 2015/0104808 A1 · Cysteine Engineered Fibronectin Type III Domain Binding Molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104808 A1
- Document ID: US20150104808A1
- Status: Published application
- Kind: A1
- Application number: 14/512,801
- Filed: 2014-10-13
- Published: 2015-04-16
- Earliest claimed: 2013-10-14
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Shalom Goldberg; Steven Jacobs; Tricia Lin
- Web page: https://patentgrep.com/patent/US20150104808A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

## Claims

### Claim 1

An isolated cysteine engineered fibronectin type III (FN3) domain comprising at least one cysteine substitution at a position selected from the group consisting of residues 6, 8, 10, 11, 14, 15, 16, 20, 30, 34, 38, 40, 41, 45, 47, 48, 53, 54, 59, 60, 62, 64, 70, 88, 89, 90, 91, and 93 of the FN3 domain, wherein the FN3 domain is based on SEQ ID NO: 1.

### Claim 2 (depends on 1)

The cysteine engineered fibronectin type III (FN3) domain according to claim 1, wherein the cysteine substitution is at a position selected from the group consisting of residues 6, 8, 10, 11, 14, 15, 16, 20, 30, 34, 38, 40, 41, 45, 47, 48, 53, 54, 59, 60, 62, 64, 70, 88, 89, 90, 91, and 93 of SEQ ID NOS: 111-114 or 122-137.

### Claim 3

An isolated cysteine engineered fibronectin type III (FN3) domain comprising the amino acid sequence of SEQ ID NO: 27 with at least one cysteine substitution from the amino acid sequence of SEQ ID NO: 27, wherein said isolated cysteine engineered FN3 domain specifically binds epidermal growth factor receptor (EGFR) and blocks binding of epidermal growth factor (EGF) to EGFR.

### Claim 4

An isolated cysteine engineered fibronectin type III (FN3) domain comprising the amino acid sequence of SEQ ID NO: 114 with at least one cysteine substitution from the amino acid sequence of SEQ ID NO: 114, wherein said isolated cysteine engineered FN3 specifically binds hepatocyte growth factor receptor (c-Met) and blocks binding of hepatocyte growth factor (HGF) to c-Met.

### Claim 5 (depends on 1)

The cysteine engineered fibronectin type III (FN3) domain according to claim 1, further comprising a half-life extending moiety.

### Claim 6 (depends on 5)

The cysteine engineered fibronectin type III (FN3) domain of claim 5, wherein the half-life extending moiety is an albumin binding molecule, a polyethylene glycol (PEG) or at least a portion of an Fc region of an immunoglobulin.

### Claim 7

A method of preparing a cysteine engineered FN3 domain comprising:
(i) mutagenizing a nucleic acid sequence of a parent FN3 domain by replacing one or more nucleotide residues with nucleotide residues encoding a cysteine amino acid residue to encode the cysteine engineered FN3 domain;
(ii) expressing the cysteine engineered FN3 domain; and
(iii) recovering the cysteine engineered FN3 domain.

### Claim 8 (depends on 7)

The method of claim 7, wherein the FN3 domain is based on SEQ ID NO: 1 and the mutagenizing step comprises performing site-directed mutagenesis.

### Claim 9 (depends on 8)

The method of claim 8, comprising expressing the cysteine engineered FN3 domain in E. coli.

### Claim 10 (depends on 8)

The method of claim 8 further comprising after the recovering step: reacting the cysteine engineered FN3 domain with a thiol-reactive chemical reagent to generate a chemically-conjugated, cysteine engineered FN3 domain.

### Claim 11 (depends on 10)

The method of claim 10, further comprising after the reacting step, measuring the EGFR binding of the chemically-conjugated, cysteine engineered FN3 domain.

### Claim 12 (depends on 11)

The method of claim 11, further comprising after the reacting step, measuring the inhibition of cell growth of an EGFR-overexpressing tumor cell line after addition of the chemically-conjugated, cysteine engineered FN3 domain.

### Claim 13 (depends on 11)

The method of claim 11, further comprising after the reacting step, measuring the c-Met binding of the chemically-conjugated, cysteine engineered FN3 domain.

### Claim 14 (depends on 11)

The method of claim 11, further comprising after the reacting step, measuring the inhibition of cell growth of an c-Met-expressing tumor cell line after addition of the chemically-conjugated, cysteine engineered FN3 domain.

### Claim 15 (depends on 11)

The method of claim 11, wherein the thiol-reactive reagent comprises a maleimide moiety.

### Claim 16 (depends on 15)

The method of claim 15, wherein the thiol-reactive reagent comprising the maleimide moiety is selected from the group consisting of NEM, MMAE, and MMAF.

### Claim 17 (depends on 16)

The method of claim 16, wherein the chemically-conjugated, cysteine engineered FN3 domain has a cell growth IC50 value between about 1.7×10−10 M and about 1.3×10−9 M when measured in EGFR-overexpressing H1573 cells.

### Claim 18

An isolated cysteine engineered fibronectin type III (FN3) domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 189-216 and 227-254.

### Claim 19

An isolated cysteine engineered bispecific FN3 molecule comprising a first fibronectin type III (FN3) domain and a second FN3 domain, wherein the first FN3 domain comprises a cysteine substitution at a position selected from the group consisting of residues 6, 8, 10, 11, 14, 15, 16, 20, 30, 34, 38, 40, 41, 45, 47, 48, 53, 54, 59, 60, 62, 64, 70, 88, 89, 90, 91, and 93 of the first FN3 domain, specifically binds epidermal growth factor receptor (EGFR) and blocks binding of epidermal growth factor (EGF) to EGFR, and the second FN3 domain specifically binds hepatocyte growth factor receptor (c-Met), and blocks binding of hepatocyte growth factor (HGF) to c-Met.

### Claim 20 (depends on 19)

The isolated cysteine engineered bispecific FN3 molecule of claim 19, wherein the second FN3 domain comprises a cysteine substitution at a position selected from the group consisting of residues 6, 8, 10, 11, 14, 15, 16, 20, 30, 34, 38, 40, 41, 45, 47, 48, 53, 54, 59, 60, 62, 64, 70, 88, 89, 90, 91, and 93 of the second FN3 domain.

### Claim 21 (depends on 20)

The isolated cysteine engineered bispecific FN3 molecule of claim 20, comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 219-226 and 257-264.

### Claim 22 (depends on 20)

The isolated cysteine engineered bispecific molecule of claim 20, wherein the molecule is chemically-conjugated to a thiol-reactive reagent.

### Claim 23 (depends on 22)

The isolated cysteine engineered bispecific molecule of claim 22, wherein the thiol-reactive reagent is a maleimide moiety.

### Claim 24 (depends on 23)

The isolated cysteine engineered bispecific molecule of claim 23, wherein the maleimide moiety is selected from the group consisting of NEM, PEG24-maleimide, fluorescein maleimide, MMAE, and MMAF.

### Claim 25 (depends on 24)

The cysteine engineered bispecific molecule of claim 24, wherein the first FN3 domain inhibits EGF-induced EGFR phosphorylation at EGFR residue Tyrosine 1173 with an IC50 value between about 0.9×10−9 M and about 2.3×10−9 M when measured in NCI-H292 cells using 50 ng/mL human EGF, and the second FN3 domain inhibits HGF-induced c-Met phosphorylation at c-Met residue Tyrosine 1349 with an IC50 value between about 4×10−10 M and about 1.3×10−9 M when measured in NCI-H292 cells using 100 ng/mL human HGF.

### Claim 26 (depends on 25)

The cysteine engineered bispecific molecule of claim 25, wherein the cysteine engineered bispecific molecule has a cell growth IC50 value selected from the group consisting of:
(i) between about 5.0×10−11 M and about 5.8×10−10 M when measured in EGFR-overexpressing H1573 cells; and
(ii) between about 7.8×10−12 M and about 1.1×10−9 M when measured in EGFR-overexpressing A731 cells.

### Claim 27 (depends on 26)

The cysteine engineered bispecific molecule according to claim 26, further comprising a half-life extending moiety.

### Claim 28 (depends on 27)

The cysteine engineered bispecific molecule of claim 27, wherein the half-life extending moiety is an albumin binding molecule, a polyethylene glycol (PEG) or at least a portion of an Fc region of an immunoglobulin.

### Claim 29

A method of preparing an isolated cysteine engineered bispecific molecule comprising:
(i) mutagenizing a nucleic acid sequence of a parent bispecific molecule by replacing one or more nucleotide residues with nucleotide residues encoding a cysteine residue to encode the cysteine engineered bispecific molecule;
(ii) expressing the cysteine engineered bispecific molecule; and
(iii) recovering the cysteine engineered bispecific molecule.

### Claim 30 (depends on 29)

The method of claim 29, wherein the mutagenizing step comprises performing site-directed mutagenesis.

### Claim 31 (depends on 30)

The method of claim 30, comprising expressing the cysteine engineered bispecific molecule in E. coli.

### Claim 32 (depends on 30)

The method of claim 30 further comprising after the recovering step, reacting the cysteine engineered bispecific molecule with a thiol-reactive chemical reagent to generate a chemically-conjugated, cysteine engineered bispecific molecule.

### Claim 33

The method of 32, further comprising a step selected from the group consisting of:
(i) measuring the EGFR binding of the chemically-conjugated, cysteine engineered bispecific molecule;
(ii) measuring the inhibition of EGF-stimulated EGFR phosphorylation in a cell line by the chemically-conjugated, cysteine engineered bispecific molecule;
(iii) measuring the inhibition of HGF-stimulated c-Met phosphorylation in a cell line by the chemically-conjugated, cysteine engineered bispecific molecule; and
(iv) measuring the inhibition of cell growth of an EGFR-overexpressing tumor cell line after addition of the chemically-conjugated, cysteine engineered bispecific molecule.

### Claim 34

Any invention described herein.
